Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07201415

Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma

To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Neovascular Glaucoma Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Retinopathy Embolism and Thrombosis Endocrine System Diseases Eye Diseases Glaucoma Glaucoma, Neovascular Ocular Hypertension Retinal Diseases Retinal Vein Occlusion Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

About this study

To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP > 21mmHg) after medical or surgical treatment

Exclusion criteria

  • Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.)
  • Eye infection within two weeks before surgery
  • Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, clinically significant macular edema, eye tumors, etc.)
  • Visual acuity of non-study eyes < 0.05
  • Congenital or acquired factors lead to ciliary body anatomical abnormalities

Treatment and study plan

minimally invasive suprachoroidal drainage

Procedure

minimally invasive suprachoroidal drainage

Primary outcomes

  1. Ocular biological parameters

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    intraocular pressure

  2. Ocular biological parameters

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    visual acuity

  3. Surgical outcome measures

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    use of intraocular pressure lowering drugs

  4. The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest

Secondary outcomes

  1. The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    Amplitude of IOP reduction: IOP change/initial IOP.The total number of IOP lowering drugs was recorded based on the number of active ingredients

  2. Surgical outcome measures

    Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery

    complications

Sponsors and collaborators

Lead sponsor

Zhongnan Hospital

Other

Registry information

Official study title

An Exploratory Study of the Efficacy and Safety of Minimally Invasive Supraporoidal Drainage for Advanced Neovascular Glaucoma

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Oct 1, 2025
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.